Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD4205 in Relapsed/Refractory Cutaneous T-cell Lymphoma
CTR20212475Phase 2Completed
- Sponsor
- Dizal Pharmaceutical Co., Ltd.
- Start
- Oct 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of golidocitinib in cutaneous T-cell lymphoma (CTCL), mycosis fungoides (MF), Sézary syndrome (SS), sponsored by Dizal Pharmaceutical Co., Ltd.. Started Oct 2021; status: completed.
02
Drugs
golidocitinib
03
Conditions
cutaneous T-cell lymphoma (CTCL)mycosis fungoides (MF)Sézary syndrome (SS)
Beyond the preview
Go deeper on CTR20212475.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20212475.